Limits...
Mitomycin C in combination with radiotherapy as a potent inhibitor of tumour cell repopulation in a human squamous cell carcinoma.

Budach W, Paulsen F, Welz S, Classen J, Scheithauer H, Marini P, Belka C, Bamberg M - Br. J. Cancer (2002)

Bottom Line: Graded top up doses (clamped blood flow: 0-57 Gy) were given at day 16, 23, 30 or 37.End point of the study was the time to local tumour progression.Mitomycin C decreased the relative risk of local recurrence by 94% (P<0.001) equivalent to 31.7 Gy top up dose.

View Article: PubMed Central - PubMed

Affiliation: Department of Radiation Oncology, University of Tuebingen, Hoppe-Seyler-Str. 3, D-72076 Tuebingen, Germany. wilfried.budach@med.uni-tuebingen.de

Show MeSH

Related in: MedlinePlus

Actuarial local tumour control after fractionated radiotherapy alone+top up irradiation (lower curve, n=117), and fractionated radiotherapy in combination with MMC+top up irradiation (upper curve, n=139) (log rank test: P<<0.001). Tick marks represent censored cases due to intercurrent death of animals. The median top up dose in the radiotherapy+MMC group was 15 Gy compared to 30 Gy in the radiotherapy alone group.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC2375212&req=5

fig4: Actuarial local tumour control after fractionated radiotherapy alone+top up irradiation (lower curve, n=117), and fractionated radiotherapy in combination with MMC+top up irradiation (upper curve, n=139) (log rank test: P<<0.001). Tick marks represent censored cases due to intercurrent death of animals. The median top up dose in the radiotherapy+MMC group was 15 Gy compared to 30 Gy in the radiotherapy alone group.

Mentions: A total of 256 animals received fractionated radiotherapy±MMC with or without top up irradiation. Locally recurrent tumours were observed in 84 out of 117 animals (71.8%) in the radiotherapy alone arm (all top up days) and in 44 out of 139 animals (31.7%) in the radiotherapy+MMC arm (all top up days) of the study (P<0.001), although the median top up doses were 15 Gy lower in the MMC arm (30 Gy vs 15 Gy) (Figure 4Figure 4


Mitomycin C in combination with radiotherapy as a potent inhibitor of tumour cell repopulation in a human squamous cell carcinoma.

Budach W, Paulsen F, Welz S, Classen J, Scheithauer H, Marini P, Belka C, Bamberg M - Br. J. Cancer (2002)

Actuarial local tumour control after fractionated radiotherapy alone+top up irradiation (lower curve, n=117), and fractionated radiotherapy in combination with MMC+top up irradiation (upper curve, n=139) (log rank test: P<<0.001). Tick marks represent censored cases due to intercurrent death of animals. The median top up dose in the radiotherapy+MMC group was 15 Gy compared to 30 Gy in the radiotherapy alone group.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC2375212&req=5

fig4: Actuarial local tumour control after fractionated radiotherapy alone+top up irradiation (lower curve, n=117), and fractionated radiotherapy in combination with MMC+top up irradiation (upper curve, n=139) (log rank test: P<<0.001). Tick marks represent censored cases due to intercurrent death of animals. The median top up dose in the radiotherapy+MMC group was 15 Gy compared to 30 Gy in the radiotherapy alone group.
Mentions: A total of 256 animals received fractionated radiotherapy±MMC with or without top up irradiation. Locally recurrent tumours were observed in 84 out of 117 animals (71.8%) in the radiotherapy alone arm (all top up days) and in 44 out of 139 animals (31.7%) in the radiotherapy+MMC arm (all top up days) of the study (P<0.001), although the median top up doses were 15 Gy lower in the MMC arm (30 Gy vs 15 Gy) (Figure 4Figure 4

Bottom Line: Graded top up doses (clamped blood flow: 0-57 Gy) were given at day 16, 23, 30 or 37.End point of the study was the time to local tumour progression.Mitomycin C decreased the relative risk of local recurrence by 94% (P<0.001) equivalent to 31.7 Gy top up dose.

View Article: PubMed Central - PubMed

Affiliation: Department of Radiation Oncology, University of Tuebingen, Hoppe-Seyler-Str. 3, D-72076 Tuebingen, Germany. wilfried.budach@med.uni-tuebingen.de

Show MeSH
Related in: MedlinePlus